BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...treat idiopathic pulmonary fibrosis and systemic sclerosis interstitial lung disease. Cel-Sci developing peptide-based COVID-19 therapy Cel-Sci Corp....
...and lung tissue damage. While many COVID-19 products in development target the virus’ spike protein, Cel-Sci...
BioCentury | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

...completion date in February 2022, according to ClinicalTrials.gov. Cel-Sci’s Multikine trial to continue in SCCHN Cel-Sci Corp....
...#), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) PCV-15 (V114) Promethera HepaStem (HepaStem) SRK-015 Bristol-Myers Squibb Co. Cel-Sci Corp. Great...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...previously treated follicular and marginal zone lymphoma in combination with Rituxan rituximab PDUFA date 6/27/19 Cel-Sci Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...CKD)-associated pruritus Phase III data 1H19 Cassiopea S.p.A. (SIX:SKIN) Winlevi clascoterone Acne Submit NDA 1H19 Cel-Sci Corp....
BioCentury | Oct 27, 2017
Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

...2015 ). Multikine is a cytokine mixture that includes interleukins, interferons, chemokines and colony-stimulating factors. Cel-Sci Corp....
...survival (PFS) and quality of life (QOL) Status: Phase III resumed Milestone: NA Allison Johnson leukocyte interleukin injection Multikine Cel-Sci Corp. Ergomed...
BioCentury | Jun 23, 2017
Clinical News

Cel-Sci submits response regarding FDA's hold on Phase III trial of Multikine

...new deficiencies. The partial hold was switched to a full clinical hold at the time. Cel-Sci...
...was working to win an arbitration case against its former CRO originally running the trial. Cel-Sci...
...colony-stimulating factors. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Product: Multikine leukocyte interleukin injection Business: Cancer Alex Himes leukocyte interleukin injection Multikine Cel-Sci Corp....
BioCentury | May 4, 2017
Financial News

Cel-Sci raises $1.5M in direct public offering

...On May 1, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale...
...9.9 million shares at $0.1214. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
BioCentury | Mar 10, 2017
Financial News

Cel-Sci completes direct public offering

...Cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale of 15 million...
...15 million shares at $0.12. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
BioCentury | Feb 24, 2017
Financial News

Cel-Sci completes private placement

...On Feb. 17, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1 million through the sale...
...10 million shares at $0.12. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alicia Parker Cel-Sci Corp....
BioCentury | Dec 2, 2016
Financial News

Cel-Sci completes private placement of common stock and warrants

...34 million shares at $0.18. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
Items per page:
1 - 10 of 246
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...treat idiopathic pulmonary fibrosis and systemic sclerosis interstitial lung disease. Cel-Sci developing peptide-based COVID-19 therapy Cel-Sci Corp....
...and lung tissue damage. While many COVID-19 products in development target the virus’ spike protein, Cel-Sci...
BioCentury | May 9, 2019
Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

...completion date in February 2022, according to ClinicalTrials.gov. Cel-Sci’s Multikine trial to continue in SCCHN Cel-Sci Corp....
...#), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) PCV-15 (V114) Promethera HepaStem (HepaStem) SRK-015 Bristol-Myers Squibb Co. Cel-Sci Corp. Great...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...previously treated follicular and marginal zone lymphoma in combination with Rituxan rituximab PDUFA date 6/27/19 Cel-Sci Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...CKD)-associated pruritus Phase III data 1H19 Cassiopea S.p.A. (SIX:SKIN) Winlevi clascoterone Acne Submit NDA 1H19 Cel-Sci Corp....
BioCentury | Oct 27, 2017
Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

...2015 ). Multikine is a cytokine mixture that includes interleukins, interferons, chemokines and colony-stimulating factors. Cel-Sci Corp....
...survival (PFS) and quality of life (QOL) Status: Phase III resumed Milestone: NA Allison Johnson leukocyte interleukin injection Multikine Cel-Sci Corp. Ergomed...
BioCentury | Jun 23, 2017
Clinical News

Cel-Sci submits response regarding FDA's hold on Phase III trial of Multikine

...new deficiencies. The partial hold was switched to a full clinical hold at the time. Cel-Sci...
...was working to win an arbitration case against its former CRO originally running the trial. Cel-Sci...
...colony-stimulating factors. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Product: Multikine leukocyte interleukin injection Business: Cancer Alex Himes leukocyte interleukin injection Multikine Cel-Sci Corp....
BioCentury | May 4, 2017
Financial News

Cel-Sci raises $1.5M in direct public offering

...On May 1, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale...
...9.9 million shares at $0.1214. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
BioCentury | Mar 10, 2017
Financial News

Cel-Sci completes direct public offering

...Cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1.5 million through the sale of 15 million...
...15 million shares at $0.12. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
BioCentury | Feb 24, 2017
Financial News

Cel-Sci completes private placement

...On Feb. 17, cancer and infectious disease company Cel-Sci Corp. (NYSE-M:CVM) raised $1 million through the sale...
...10 million shares at $0.12. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alicia Parker Cel-Sci Corp....
BioCentury | Dec 2, 2016
Financial News

Cel-Sci completes private placement of common stock and warrants

...34 million shares at $0.18. H.C. Wainwright was the placement agent. Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Alex Himes Cel-Sci Corp....
Items per page:
1 - 10 of 246